News | Contrast Media | August 14, 2020

The first and only FDA-approved gadolinium-based contrast agent for multi-patient dosing with an FDA-cleared Transfer Spike in the MR suite

The first and only FDA-approved gadolinium-based contrast agent for multi-patient dosing with an FDA-cleared Transfer Spike in the MR suite

August 14, 2020 — The U.S. Food and Drug Administration (FDA) announced the approval of the Gadavist (gadobutrol) Imaging Bulk Package. The Gadavist Imaging Bulk Package will be available in two presentation sizes, 30 mL and 65 mLand allows for weight-based dosing with a 24-hour stand time for multi-patient dosing.

In conjunction with the bulk package approval, the FDA also cleared the MEDRAD Imaging Bulk Package Transfer Spike that is indicated for the transfer of Gadavist contrast media as supplied in the Imaging Bulk Package presentation.

As the only MR contrast media FDA-approved Imaging Bulk Package for use with a cleared transfer spike, Gadavist Imaging Bulk Package offers key features to support the radiology workflow. After initial set up, the product can be used across multiple patients and work shifts for up to 24 hours after the first puncture of the Imaging Bulk Package. Compared to single-use bottles, the Imaging Bulk Package can potentially mean more complete usage of the contrast and less contrast and vial waste. In addition, technologists and nurses can prepare and administer weight-based dosing using a single multi-dose set up directly in the scan room. The bulk package adheres to the Joint Commission requirements for multi-patient dosing.1

“With the changing healthcare environment, Bayer is dedicated to investing not only in new innovations, but aligning our solutions to address some of the challenges that hospitals are facing today,” said Dennis Durmis, Head of Region Americas, Bayer Radiology. "We are focused on offering solutions in new areas of unmet need."

Sentinel Event Alert 52: Preventing infection from the misuse of vials. The Joint Comission web site. https://www.jointcommission.org/en/resources/patient-safety-topics/sentinel-event/sentinel-event-alert-newsletters/sentinel-event-alert-issue-52-preventing-infection-from-the-misuse-of-vials/. Accessed August 11, 2020.

For more information: www.bayer.com

Related Content

News | Computed Tomography (CT)

August 15, 2022 — According to ARRS’ American Journal of Roentgenology (AJR), the combination of deep-learning ...

Time August 15, 2022
arrow
News | Ultrasound Imaging

August 10, 2022 — Butterfly Network, Inc., a digital health company transforming care with handheld, whole-body ...

Time August 10, 2022
arrow
Feature | Magnetic Resonance Imaging (MRI) | Christine Book

August 10, 2022 — The imaging community has lost a legend, recognized for having revolutionized the field of diagnostic ...

Time August 10, 2022
arrow
News | Prostate Cancer

August 9, 2022 — Bot Image, an Omaha-based MRI medical device company has developed an AI-driven medical device CAD ...

Time August 09, 2022
arrow
News | Contrast Media

August 3, 2022 — According to an open-access article in ARRS’ American Journal of Roentgenology (AJR), electronic health ...

Time August 03, 2022
arrow
News | Contrast Media

August 2, 2022 – A new update has been announced as the radiology world continues to address supply disruptions of ...

Time August 02, 2022
arrow
Feature | Radiology Business | By Melinda Taschetta-Millane

Here is what you and your colleagues found to be most interesting in the field of medical imaging during the month of ...

Time August 01, 2022
arrow
News | Mobile C-Arms

July 29, 2022 — Siemens Healthineers has announced the Food and Drug Administration (FDA) clearance of the ARTIS icono ...

Time July 29, 2022
arrow
News | Artificial Intelligence

July 26, 2022 — Aidoc, a leading provider of AI healthcare solutions, today announced a partnership with UofL Health, a ...

Time July 26, 2022
arrow
Feature | AHRA | By Melinda Taschetta-Millane

The Association for Medical Imaging Management (AHRA) celebrated its 50th anniversary July 10-13, 2022, in Phoenix. To ...

Time July 25, 2022
arrow
Subscribe Now